• Explore /
  • Poster
  • / Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

Abstract Video & Slides Poster

Authors

Erika Hamilton

Erika P. Hamilton

Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN

Erika P. Hamilton , Judy S. Wang , Timothy J. Pluard , Stephen R. D. Johnston , Aki Morikawa , Elizabeth Claire Dees , Robert Hugh Jones , Barbara B. Haley , Anne Caroline Armstrong , Adam Louis Cohen , Pamela N. Munster , Gail Lynn Shaw Wright , Fadi Kayali , Manav Korpal , Jianjun Alan Xiao , Jenny Long , Benoit Destenaves , Lei Gao , Antonio Gualberto , Dejan Juric

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT03250676

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 1018)

DOI

10.1200/JCO.2021.39.15_suppl.1018

Abstract #

1018

Abstract Disclosures

Similar Posters

First Author: Erika P. Hamilton

First Author: Kelvin K H Bao

First Author: Mario Campone

First Author: Elisabeth De Vries